Tirzepatide may deliver cardiorenal benefits after TAVR in patients with obesity

Summary: People with obesity who get a heart valve replacement (called TAVR) often face risks like heart failure or kidney problems after the procedure. A new study shows that taking the weight-loss and diabetes medicine tirzepatide (also known as Mounjaro or Zepbound) can help lower these risks. Patients taking this drug had a much lower chance of heart failure and kidney injury one year after their surgery compared to those who did not take it. The medicine helps by causing weight loss, lowering blood pressure, and reducing body swelling. Doctors think that treating a patient's overall health with this medicine can make their heart surgery recovery much safer and easier.

For more details, see rssapp-healio-com at healio.com/news/cardiology/20260514/tirzepatide-may-deliver-cardiorenal-benefits-after-tavr-in-patients-with-obesity (opens in new tab)